WO2005011697A3 - Sulfonamide derivatives with activity on protein kinase a and b - Google Patents
Sulfonamide derivatives with activity on protein kinase a and b Download PDFInfo
- Publication number
- WO2005011697A3 WO2005011697A3 PCT/GB2004/003196 GB2004003196W WO2005011697A3 WO 2005011697 A3 WO2005011697 A3 WO 2005011697A3 GB 2004003196 W GB2004003196 W GB 2004003196W WO 2005011697 A3 WO2005011697 A3 WO 2005011697A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen
- carbon atoms
- optionally substituted
- length
- protein kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides compounds for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A or protein kinase B, the compounds having the formula (I°), or being salts or solvates thereof. In formula (I°), n is 0 or 1; A and E are alkylene 2-3 carbon atoms in length optionally substituted by R11 and -X-CH(R6)(R7); G is hydrogen when n is 0 and, when n is 1, G is hydrogen or -X-CH(R6)(R7); R1 is an aryl or heteroaryl group having 5-12 ring members; R2 and R4 are selected from hydrogen, R7, R11 and CH(R6)(R7); R3, R3a and R5 are selected from hydrogen, R11 and -X-CH(R6)(R7); or any one pair or any two non-overlapping pairs selected from R2 and R3; R3 and R4; R2 and R5; R3 and R5; R4 and R5; R3 and R8; and R4 and R8 are linked together in a ring and together form an alkylene chain of 1-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or the pair R2 and R4 are linked together in a ring and together form an alkylene chain of 2-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); and optionally R3 and R3a may be linked together in a ring and together form an alkylene chain of 1-6 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or R6 and R7 together with the carbon atom to which they are attached form a cyclic group having 5-12 ring members; X, R6, R7, R8, R9, R10 and R11 are each as defined in claim 1; and wherein the definitions of, A, E, G, X, n and R1 to R11 are subject to the provisos set ou in claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0317315A GB0317315D0 (en) | 2003-07-24 | 2003-07-24 | Pharmaceutical compounds |
| GB0317315.0 | 2003-07-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005011697A2 WO2005011697A2 (en) | 2005-02-10 |
| WO2005011697A3 true WO2005011697A3 (en) | 2005-04-21 |
Family
ID=27772571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2004/003196 Ceased WO2005011697A2 (en) | 2003-07-24 | 2004-07-23 | Sulfonamide derivatives with activity on protein kinase a and b |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0317315D0 (en) |
| WO (1) | WO2005011697A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9068166B2 (en) | 2010-09-16 | 2015-06-30 | Industry-Academic Cooperation Foundation Yonsei University | Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7449477B2 (en) | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| US7618984B2 (en) | 2005-08-30 | 2009-11-17 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| AR061240A1 (en) | 2006-06-20 | 2008-08-13 | Lilly Co Eli | COMPOUNDS OF 4-ISOQUINOLIN-PHENOL, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS ANTINEOPLASIC AND / OR ANTIVIRAL AGENTS. |
| WO2008105058A1 (en) | 2007-02-27 | 2008-09-04 | Asahi Kasei Pharma Corporation | Sulfonamides |
| JP5313125B2 (en) | 2007-02-28 | 2013-10-09 | 旭化成ファーマ株式会社 | Sulfonamide derivatives |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| AU2008272396B2 (en) | 2007-07-02 | 2011-09-08 | Asahi Kasei Pharma Corporation | Sulfonamide Compound and Crystal Thereof |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2248235A (en) * | 1988-12-26 | 1992-04-01 | Hiroyoshi Hidaka | Quinoline-sulphonamides having smooth muscle relaxation activity |
| WO2001091754A1 (en) * | 2000-05-30 | 2001-12-06 | Peptor Ltd. | Protein kinase inhibitors |
-
2003
- 2003-07-24 GB GB0317315A patent/GB0317315D0/en not_active Ceased
-
2004
- 2004-07-23 WO PCT/GB2004/003196 patent/WO2005011697A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2248235A (en) * | 1988-12-26 | 1992-04-01 | Hiroyoshi Hidaka | Quinoline-sulphonamides having smooth muscle relaxation activity |
| WO2001091754A1 (en) * | 2000-05-30 | 2001-12-06 | Peptor Ltd. | Protein kinase inhibitors |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9068166B2 (en) | 2010-09-16 | 2015-06-30 | Industry-Academic Cooperation Foundation Yonsei University | Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0317315D0 (en) | 2003-08-27 |
| WO2005011697A2 (en) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200600225A1 (en) | DERIVATIVES OF PIPERAZINE FOR THE TREATMENT OF HIV INFECTIONS | |
| CY1109890T1 (en) | 8-Substituted-6,7,8,9-tetrahydropyrimide [1,2-a] pyrimidin-4-one derivative | |
| NO20071642L (en) | N-Benzenesulfonyl-substituted anilino-pyrimidine analogs | |
| CY1105554T1 (en) | 3- SUBSTITUTE-4-PYRIMIDONE DERIVATIVES | |
| DE602004014347D1 (en) | CHINAZOLIN DERIVATIVES AS TGF BETA INHIBITORS | |
| CY1118526T1 (en) | DYDROPYROZOLOPYRIMININONE PRODUCTS | |
| WO2005011697A3 (en) | Sulfonamide derivatives with activity on protein kinase a and b | |
| DK1260512T3 (en) | Hitherto unknown cyclic amide derivatives | |
| CY1112214T1 (en) | UNITS FOR USE INJURED WITH INFLAMMATES AND IMMUNE | |
| MX2007000505A (en) | Substituted oxindol derivatives and medicaments containing the same. | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| NO20071719L (en) | Pyridyl inhibitors for "hedgehog" signaling | |
| HRP20050073A2 (en) | Pyridines and pyrimidines substituted by 4-trifluoromethylpyrazolyl | |
| TW200718422A (en) | 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | |
| TW200605883A (en) | Condensed heterocycle derivative having HCV inhibitory activity | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| MX339668B (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor. | |
| TW200740752A (en) | 4-Biarylyl-1-phenylazetidin-2-ones | |
| NO20076145L (en) | Ureadeviates, processes for their preparation and use thereof | |
| WO2005111002A3 (en) | Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases | |
| MX2010008361A (en) | Substituted arylamide oxazepinopyrimidone derivatives. | |
| TW200630374A (en) | Thiazolyldihydroindazoles | |
| DE602006020152D1 (en) | ARYL ALKYL AND HETEROARYL ALKYL DERIVATIVES OF CYCLOSPORIN A IN THE TREATMENT AND PREVENTION OF VIRUS INFECTION | |
| ATE503746T1 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
| WO2003082861A3 (en) | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |